2 European Courts Reject Fosamax Patents

Law360, New York (February 25, 2008, 12:00 AM EST) -- In a double whammy for a Merck & Co. subsidiary, two European courts have separately knocked down the drug manufacturer’s key patent covering a generic version of its osteoporosis drug Fosamax, according to a rival maker of generic drugs.

Teva Pharmaceutical Industries Ltd. said Monday that courts in the Netherlands and France have each found Merck Sharp & Dohme’s European patent related to alendronate to be invalid.

The Hague District Court revoked Merck’s European Patent Number 1,175,904 on Feb. 13 after determining it lacked inventive step,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.